Mazdutide
GLP-1/glucagon dual agonist · Also known as IBI362, LY3305677, Oxyntomodulin analog
What is Mazdutide?
A dual GLP-1 and glucagon receptor agonist developed by Innovent Biologics. Approved in China for obesity, it combines the appetite suppression of GLP-1 drugs with the fat-burning effects of glucagon activation.
Mazdutide is a long-acting oxyntomodulin analog that activates both the GLP-1 receptor (reducing appetite, improving insulin sensitivity) and the glucagon receptor (increasing energy expenditure, promoting fat oxidation). In Phase 3 trials, it achieved up to 15.5% weight loss at 48 weeks.
Benefits & evidence
How it works
Mazdutide acts on two receptors simultaneously. GLP-1 receptor activation suppresses appetite via hypothalamic signaling, slows gastric emptying, and improves pancreatic beta-cell function.
Glucagon receptor activation increases hepatic glucose output in the short term, but more importantly promotes lipolysis and thermogenesis, increasing energy expenditure. The combination means patients lose more fat mass relative to lean mass compared to GLP-1-only drugs like semaglutide.
The glucagon component may also reduce liver fat accumulation, making mazdutide particularly interesting for metabolic-associated fatty liver disease (MAFLD).
Dosing information
Typical dosing protocol
3 mg weekly
4 weeks6-9 mg weekly
OngoingDose escalation over 4-8 weeks to minimize GI side effects. Approved in China at 6 mg and 9 mg doses.
Side effects
Most side effects tend to improve as your body adjusts.